

(Company Code 7702)

JMS CO.,LTD.

Financial Statements
for the 3rd Quarter of Fiscal Year Ending March 31, 2026
(From Apr. 1, 2025 to Dec. 31, 2025)

Summary of consolidated results

February 6, 2026

Summary of Financial Results

Consolidated	Net sales	48,975million yen ((3,660) million yen)
Decrease in sales	Operating profit	189million yen ((630) million yen)
Decrease in profit		

Sales : Although oncology therapy and enteral nutrition continued to grow in Japan, net sales decreased due to a decline in core products in the Blood Management & Cell Therapy overseas

Profit : Decreased profit due to the impact of reduced sales of core products overseas

Sales by Business Segment

Blood Management & Cell Therapy : Sales of Apheresis Kits for North America and Blood Bags for Africa and Asia decreased

Infusion & Nutrition: Although Closed Drug Mixing/Infusion Systems and Dysphagia-related products performed steadily, sales decreased due to strategic review of transactions for Medical Gloves and Urinary Drainage products

Sales by Region

North America : Apheresis Kits decreased due to inventory adjustments by major customers


Asia: Blood Bags, Hemodialysis Machines, and AV Fistula Needles in the Chinese domestic market decreased

Highlights in Business Results


(unit: JPY million)

	Apr. - Dec. 2024 Results	Apr. - Dec. 2025 Results	Year – over – Year	
			Diff.	%
Net sales	52,635	48,975	(3,660)	(7.0)%
Operating profit	819	189	(630)	(76.9)%
Ordinary profit	632	275	(357)	(56.5)%
Profit attributable to owners of parent	209	(104)	(313)	—


Net sales




Operating profit



Ordinary profit



Profit attributable to owners of parent



Summary by segment (geographical area)

[Singapore] Although sales of Apheresis Kits for North America and Blood Bags for Africa and Asia decreased, resulting in reduced sales impact, losses narrowed due to decreased foreign exchange losses

[Japan] Although Closed Drug Mixing/Infusion Systems and Dysphagia-related products continued to grow, profit decreased due to declines in Blood Purification Systems and Hemodialysis Machines for China

(unit: JPY million)

		Apr. - Dec. 2024	Apr. - Dec. 2025	Year – over - Year	
				Diff.	%
Japan	Sales	34,942	33,973	(968)	(2.8)%
	Ordinary profit	1,150	599	(551)	(47.9)%
Singapore※	Sales	19,762	17,061	(2,701)	(13.7)%
	Ordinary profit	(255)	(116)	138	—
China	Sales	3,167	3,060	(106)	(3.4)%
	Ordinary profit	(7)	127	135	—
Philippines	Sales	2,853	2,536	(316)	(11.1)%
	Ordinary profit	(277)	(537)	(259)	—
Germany	Sales	3,328	2,977	(350)	(10.5)%
	Ordinary profit	338	345	6	1.9%
Others※	Sales	3,711	4,331	620	16.7%
	Ordinary profit	(272)	(192)	79	—

※Singapore : This segment includes Indonesian subsidiary.

※Others : This segment includes business activity of subsidiaries in Japan, United States, South Korea , Thailand and Part of China.

(unit: JPY million)

Infusion & Nutrition

18,569 18,170



Net sales


■ Apr. - Dec. 2024 ■ Apr. - Dec. 2025

Although Closed Drug Mixing/Infusion Systems and Dysphagia-related products performed steadily, sales decreased due to strategic review of transactions for Medical Gloves and Urinary Drainage products



Dialysis

16,351 16,332



Net sales


■ Apr. - Dec. 2024 ■ Apr. - Dec. 2025

Although AV Fistula Needles for Europe and North America performed well, Hemodialysis Machines for China decreased



Cardiovascular

4,102 3,905



Net sales

■ Apr. - Dec. 2024 ■ Apr. - Dec. 2025

Cardiopulmonary-related products and Blood Purification Systems decreased



Blood Management & Cell Therapy

12,550



Net sales

■ Apr. - Dec. 2024 ■ Apr. - Dec. 2025

Apheresis Kits for North America and Blood Bags for Africa and Asia decreased




Sales change by Region (Customer's Location)

Although Closed Drug Mixing/Infusion Systems and Dysphagia-related products performed well in Japan, and AV Fistula Needles sales were strong in Europe and North America, Apheresis Kits for North America and Blood Bags for Asia decreased

(unit: JPY million)

	Apr. - Dec. 2024	Apr. - Dec. 2025	Year – over - Year		Sales composition
			Diff.	%	
Japan	30,146	30,272	126	0.4%	61.8%
Asia	9,537	7,704	(1,833)	(19.2)%	15.7%
North America	6,045	3,486	(2,559)	(42.3)%	7.1%
Europe	4,931	6,020	1,088	22.1%	12.3%
Others	1,974	1,492	(482)	(24.4)%	3.0%




Ordinary profit : Compared with the previous year

Gross profit decreased due to reduced sales of core overseas products; although there were positive factors such as decreased selling, general and administrative expenses and investment gains, ordinary profit decreased

(unit: JPY million)

*The underlined figures exclude impact of exchange rate.



	Exchange Rate (average during period)		
	US Dollar	Euro	(unit: JPY) Singapore Dollar
Apr. - Dec. 2024	152.57	164.40	114.25
Apr. - Dec. 2025	148.74	165.54	114.97

Forecast for FYE Mar. 2026

Based on the results for the nine months ended December 2025, we have revised the consolidated earnings forecast for the fiscal year ending March 31, 2026.

(unit: JPY million)

	FYE Mar. 2025 Result	FYE Mar. 2026 Forecast		Year - over - Year %
		Previous Forecast	New Forecast	
Net sales	69,749	66,000	65,000	(6.8)%
Operating profit	872	500	200	(77.1)%
Ordinary profit	514	300	200	(61.2)%
Profit attributable to owners of parent	89	100	(800)	—

* Exchange rate for the forecast: 1USD=152yen, 1EUR= 169 yen, 1SGD= 121 yen.

- Sales :** Although core products in the Blood Management & Cell Therapy field overseas are expected to continue declining, the decrease in net sales is expected to be limited due to continued growth in oncology therapy and enteral nutrition in Japan and strong performance of AV Fistula Needles for Europe and North America
- Profit :** Although we are proceeding with price pass-through measures in response to inflation and streamlining unprofitable product lines, profit is expected to decrease due to the impact of reduced sales
As part of structural reforms, we expect to record extraordinary losses of approximately 700 million yen (estimated amount) related to the disposal of fixed assets and inventories at our Korean production facility



The Bridge to Good Health Care

The assessment figures described on this report are based on available information at this moment, including uncertain data. Actual results may be different from the figures.